INDICATORS ON BCAT-IN-4 YOU SHOULD KNOW

MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To guage various intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Primary trial targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suffere